- Trials with a EudraCT protocol (241)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
241 result(s) found for: Cohort Studies.
Displaying page 1 of 13.
EudraCT Number: 2020-005114-18 | Sponsor Protocol Number: MK-1308A-008 | Start Date*: 2021-07-20 | ||||||||||||||||
Sponsor Name:Merck Sharp & Dohme LLC | ||||||||||||||||||
Full Title: A Phase 2, Multicenter, Multi Arm, Study to Evaluate MK-1308A (Co-formulated quavonlimab (MK-1308)/pembrolizumab) Versus Other Treatments in Participants with Microsatellite Instability-High (MSI-... | ||||||||||||||||||
Medical condition: Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Trial now transitioned) PL (Trial now transitioned) BE (Ongoing) IT (Ongoing) ES (Ongoing) DK (Trial now transitioned) GR (Trial now transitioned) HU (Trial now transitioned) LT (Trial now transitioned) NL (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004827-29 | Sponsor Protocol Number: VX14-661-110 | Start Date*: 2015-09-01 | |||||||||||
Sponsor Name:Vertex Pharmaceuticals Incorporated | |||||||||||||
Full Title: A Phase 3, Open-label, Rollover Study to Evaluate the Safety and Efficacy of Long term Treatment With VX 661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, ... | |||||||||||||
Medical condition: Cystic Fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) IE (Completed) GB (GB - no longer in EU/EEA) BE (Completed) SE (Completed) AT (Completed) FR (Completed) DK (Completed) NL (Completed) DE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-020413-90 | Sponsor Protocol Number: VX09-809-102 | Start Date*: 2011-01-06 | |||||||||||
Sponsor Name:Vertex Pharmaceuticals Incorporated | |||||||||||||
Full Title: A Phase 2, Multicenter, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Lumacaftor Monotherapy, and L... | |||||||||||||
Medical condition: Cystic Fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) GB (Completed) IE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-005533-38 | Sponsor Protocol Number: ABR 14828 | Start Date*: 2007-06-28 |
Sponsor Name:there is no sponsor. | ||
Full Title: 'Studies in patients with chronic cough; montelukast and amitriptyline studies’. | ||
Medical condition: Chronic cough ( cough lasting > 8 weeks). | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2009-011464-11 | Sponsor Protocol Number: VX08-950-112 | Start Date*: 2009-10-20 | |||||||||||
Sponsor Name:Vertex Pharamceuticals, Inc. | |||||||||||||
Full Title: EXTEND: A 3-Year, Virology, Follow-up Study in Subjects Previously Treated With Telaprevir in Select Clinical Studies | |||||||||||||
Medical condition: Hepatitis C virus infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001108-40 | Sponsor Protocol Number: MK-5475-007 | Start Date*: 2021-04-08 | |||||||||||
Sponsor Name:Merck Sharp & Dohme LLC | |||||||||||||
Full Title: A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of MK-5475 in Adults with Pulmonary Arterial Hypertension | |||||||||||||
Medical condition: Pulmonary arterial hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) FR (Trial now transitioned) PL (Trial now transitioned) IT (Ongoing) GR (Trial now transitioned) BE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-004072-10 | Sponsor Protocol Number: MO11/9803 | Start Date*: 2012-07-24 |
Sponsor Name:University of Leeds | ||
Full Title: FGFR Inhibition for Epithelial Solid Tumours: a Phase Ib trial of AZD4547 in combination with gemcitabine and cisplatin | ||
Medical condition: Epithelial Solid Tumours. Locally advanced and/or metastatic transitional cell carcinoma (pure or mixed histology) of (upper or lower) urinary tract, including bladder cancer. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-001392-78 | Sponsor Protocol Number: GS-US-418-3898 | Start Date*: 2017-01-30 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: Combined Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately ... | |||||||||||||
Medical condition: Moderately to Severely Active Ulcerative Colitis (UC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) GB (Completed) BE (Completed) SE (Completed) AT (Completed) PT (Completed) GR (Completed) SK (Completed) IS (Completed) ES (Completed) BG (Completed) DE (Completed) NL (Completed) HR (Completed) NO (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002529-27 | Sponsor Protocol Number: D5339C00001 | Start Date*: 2021-02-24 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Modular Phase 2a Multicentre Open-Label Study to Investigate DNA-damage Response Agents (or Combinations) in Patients With Advanced Cancer Whose Tumours Contain Molecular Alterations (PLANETTE) | |||||||||||||
Medical condition: Advanced Cancer Whose Tumours Contain Molecular Alterations | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001367-36 | Sponsor Protocol Number: GS-US-419-3895 | Start Date*: 2017-02-08 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to ... | |||||||||||||
Medical condition: Moderately to Severely Active Crohn’s Disease (CD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) BG (Completed) AT (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) IS (Ongoing) SE (Completed) DE (Completed) GR (Completed) PT (Completed) SK (Completed) ES (Completed) BE (Completed) NL (Completed) HR (Completed) NO (Completed) IT (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-000604-41 | Sponsor Protocol Number: VX12-809-105 | Start Date*: 2014-01-21 | |||||||||||
Sponsor Name:Vertex Pharmaceuticals Incorporated | |||||||||||||
Full Title: A Phase 3, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygo... | |||||||||||||
Medical condition: Cystic fibrosis in patients homozygous or heterozygous for the F508del-CFTR Mutation | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) CZ (Completed) SE (Completed) AT (Completed) BE (Completed) GB (Completed) DE (Completed) NL (Completed) ES (Completed) IE (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001549-26 | Sponsor Protocol Number: TRASTS | Start Date*: 2014-11-03 |
Sponsor Name:GEIS | ||
Full Title: Phase I-II prospective trial, multicenter, open label, exploring the combination of Trabectedin plus Radiotherapy in Soft Tissue Sarcoma patients. | ||
Medical condition: Soft Tissue Sarcoma | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) IT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-004930-39 | Sponsor Protocol Number: G1T28-208 | Start Date*: 2021-05-28 | |||||||||||||||||||||
Sponsor Name:G1 Therapeutics, Inc. | |||||||||||||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metasta... | |||||||||||||||||||||||
Medical condition: Locally Advanced Unresectable or Metastatic Triple Negative Breast Cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: ES (Temporarily Halted) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000206-17 | Sponsor Protocol Number: COVID19_7 | Start Date*: 2021-03-10 |
Sponsor Name:Karolinska University Hospital | ||
Full Title: Studies of ongoing and completed SARS-CoV-2 infection (which causes COVID-19) within the healthcare in Stockholm County, with regard to vaccinations. | ||
Medical condition: Vaccination against COVID-19. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2015-001644-11 | Sponsor Protocol Number: VX15-809-110 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Vertex Pharmaceuticals Incorporated | |||||||||||||
Full Title: A Phase 3, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Years and Older With Cystic Fibrosis, Homozy... | |||||||||||||
Medical condition: Cystic Fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Ongoing) GB (Completed) BE (Completed) DK (Completed) DE (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002932-18 | Sponsor Protocol Number: 42756493-BLC3001 | Start Date*: 2018-02-08 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations | |||||||||||||
Medical condition: Advanced Urothelial Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) BE (Trial now transitioned) HU (Completed) ES (Ongoing) AT (Completed) FR (Trial now transitioned) DE (Ongoing) NL (Ongoing) PT (Ongoing) GR (Ongoing) PL (Completed) IT (Ongoing) DK (Ongoing) BG (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002839-66 | Sponsor Protocol Number: IMVT-1401-3203 | Start Date*: 2023-09-07 | |||||||||||
Sponsor Name:Immunovant Sciences, GmbH | |||||||||||||
Full Title: An Open-label Extension Study for Participants who Completed Study IMVT-1401-3201 or Study IMVT-1401-3202 to Assess the Efficacy and Safety of Batoclimab for the Treatment of Thyroid Eye Disease (TED) | |||||||||||||
Medical condition: Thyroid Eye Disease (TED) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Not Authorised) LV (Ongoing) BE (Ongoing) HU (Ongoing) SK (Ongoing) IT (Ongoing) ES (Ongoing) PL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001225-41 | Sponsor Protocol Number: M14-430 | Start Date*: 2018-04-17 | |||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo- Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohn's Disease who Comp... | |||||||||||||
Medical condition: Crohn's Disease (CD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Trial now transitioned) DK (Trial now transitioned) AT (Trial now transitioned) DE (Ongoing) SE (Trial now transitioned) LV (Ongoing) GB (GB - no longer in EU/EEA) PT (Ongoing) FR (Trial now transitioned) HU (Ongoing) NL (Trial now transitioned) IE (Completed) LT (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) BG (Completed) BE (Trial now transitioned) SI (Completed) HR (Ongoing) IT (Ongoing) RO (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005899-36 | Sponsor Protocol Number: CLOU064C12301 | Start Date*: 2022-02-21 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by... | |||||||||||||
Medical condition: Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Ongoing) IT (Ongoing) ES (Ongoing) NL (Ongoing) BE (Ongoing) BG (Ongoing) LV (Ongoing) HR (Ongoing) LT (Ongoing) AT (Ongoing) DK (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005929-89 | Sponsor Protocol Number: CLOU064C12302 | Start Date*: 2022-02-01 |
Sponsor Name:Novartis Pharma AG | ||
Full Title: A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by... | ||
Medical condition: Multiple Sclerosis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: SE (Ongoing) IT (Ongoing) GR (Ongoing) ES (Ongoing) PT (Ongoing) SI (Ongoing) SK (Ongoing) BG (Ongoing) PL (Ongoing) HR (Ongoing) EE (Ongoing) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.